New Data for XL880, XL647 and XL184 to Be Presented at AACR...(anced solid malignancies (ASM) (Abstract...),Health

-- A Phase I dose-escalation study of the safety, pharmacokinetics (PK)

and pharmacodynamics of XL880, a VEGFR and MET kinase inhibitor,

administered daily to patients (pts) with advanced malignancies

(Abstract #B248)

Preclinical Abstracts

-- XL820 inhibits mutated forms of KIT associated with drug resistance

(Abstract #B237)

-- In vitro and in vivo potentiation of cytotoxic therapy by XL844, an

orally bioavailable inhibitor of Chk1 and Chk2 (Abstract #B228)

-- XL518, a Potent Selective Orally Bioavailable MEK1 Inhibitor,

Downregulates the RAS/RAF/MEK/ERK Pathway In Vivo, Resulting in Tumor

Growth Inhibition and Regression in Pre-Clinical Models (Abstract

#C209)

-- Potentiating the antitumor effects of chemotherapy with the selective

PI3K inhibitor XL147 (Abstract #C199)

-- XL765 targets tumor growth, survival, and angiogenesis in preclinical

models by dual inhibition of PI3K and mTOR (Abstract #B250)

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.